Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) – Equities research analysts at Cantor Fitzgerald lowered their FY2018 earnings estimates for Progenics Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 3rd. Cantor Fitzgerald analyst M. Goldstein now expects that the biotechnology company will earn ($0.77) per share for the year, down from their prior forecast of ($0.51). Cantor Fitzgerald has a “Buy” rating and a $15.00 price objective on the stock.
Other equities analysts also recently issued research reports about the company. BidaskClub raised Progenics Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Zacks Investment Research raised Progenics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a research report on Thursday, January 4th. Finally, ValuEngine downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating, three have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $12.35.
Progenics Pharmaceuticals stock opened at $7.09 on Friday. The company has a quick ratio of 6.31, a current ratio of 6.31 and a debt-to-equity ratio of 0.74. The firm has a market cap of $528.98, a price-to-earnings ratio of -7.88 and a beta of 2.46. Progenics Pharmaceuticals has a fifty-two week low of $4.60 and a fifty-two week high of $8.64.
Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The company had revenue of $3.90 million during the quarter, compared to the consensus estimate of $3.18 million. Progenics Pharmaceuticals had a negative return on equity of 87.30% and a negative net margin of 436.08%. Progenics Pharmaceuticals’s revenue was down 15.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.10) earnings per share.
Large investors have recently made changes to their positions in the company. Fox Run Management L.L.C. purchased a new stake in shares of Progenics Pharmaceuticals in the fourth quarter valued at $100,000. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Progenics Pharmaceuticals in the fourth quarter valued at $101,000. Teacher Retirement System of Texas purchased a new stake in shares of Progenics Pharmaceuticals in the fourth quarter valued at $142,000. Millennium Management LLC purchased a new stake in shares of Progenics Pharmaceuticals in the fourth quarter valued at $169,000. Finally, MetLife Investment Advisors LLC purchased a new stake in shares of Progenics Pharmaceuticals in the fourth quarter valued at $192,000. 83.67% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/08/fy2018-earnings-forecast-for-progenics-pharmaceuticals-inc-pgnx-issued-by-cantor-fitzgerald.html.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.